Labour induction for termination of pregnancy with severe fetal anomalies after 24 weeks' gestation: a case series and systematic review of the literature

Eur J Contracept Reprod Health Care. 2022 Dec;27(6):486-493. doi: 10.1080/13625187.2022.2102604. Epub 2022 Jul 28.

Abstract

Purpose: Under some circumstances, individuals choose to undergo pregnancy termination for foetal anomalies in the second half of pregnancy. This report provides objective information on the clinical management of such cases and a systematic review of the literature on labour induction outcomes for third-trimester abortion using mifepristone-misoprostol.

Materials and methods: The study is a case series describing outcomes for labour induction abortion for foetal anomalies, at gestational age 24 weeks and beyond. A systematic review was performed, searching PubMed, Embase, and Cochrane databases. Two independent authors reviewed and quality assessed the data from the articles.

Results: During a two-year period, 15 patients met inclusion criteria. Fourteen patients received mifepristone and misoprostol, and one received oxytocin. All delivered vaginally. Thirteen patients delivered within 24 hours of the first misoprostol dose, and half delivered within 12 hours. The average interval from misoprostol initiation to foetal expulsion was 15.5 hours in our series. The systematic review identified nine articles for inclusion, all retrospective studies. Labour induction protocols for mifepristone-misoprostol, reporting of gestational age, and key comparisons varied greatly.

Conclusions: The case series illustrates successful termination of pregnancy primarily using combined mifepristone-misoprostol. Certainty of current evidence is low, based on the GRADE framework. Future research is necessary on third-trimester outcomes with mifepristone-misoprostol.

Keywords: Abortion; labour induction; mifepristone; misoprostol; second trimester; third trimester.

Publication types

  • Systematic Review

MeSH terms

  • Abortifacient Agents, Nonsteroidal* / therapeutic use
  • Abortion, Induced* / methods
  • Female
  • Gestational Age
  • Humans
  • Infant
  • Labor, Induced / methods
  • Mifepristone / therapeutic use
  • Misoprostol* / therapeutic use
  • Pregnancy
  • Pregnancy Trimester, Second
  • Retrospective Studies

Substances

  • Misoprostol
  • Mifepristone
  • Abortifacient Agents, Nonsteroidal